Literature DB >> 8236802

Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams.

J M Blasco1, C Gamazo, A J Winter, M P Jiménez de Bagüés, C Marín, M Barberán, I Moriyón, B Alonso-Urmeneta, R Díaz.   

Abstract

Five antigen preparations from Brucella ovis strain REO 198 were incorporated with the pluronic polymer L-121 and muramyl dipeptide and tested as vaccines against B. ovis infection of rams. The antigenic preparations were: (1) a fraction enriched in outer membrane proteins and rough lipopolysaccharide (hot saline extract, HS); (2) the proteins from HS substantially free of lipopolysaccharide; (3) outer membrane blebs; (4) outer membrane-peptidoglycan complexes extracted with detergent; (5) killed whole cells. The experimental vaccines were compared with two standard vaccines, rough Brucella abortus 45/20 whole killed cells in an oil based adjuvant, and live Brucella melitensis Rev 1. Immunizations with non-living vaccines were performed on two occasions, 18 weeks apart. The rams were challenged with a virulent strain of B. ovis 31 weeks after the second vaccination and slaughtered 15 weeks thereafter. Rates of infection in groups vaccinated with Rev 1 (33%), and HS (40%) were significantly lower (P < 0.005 and P < 0.025, respectively) than that in the non-vaccinated control group (87%). Strain 45/20 was the only other vaccine that conferred a significant level of protection (50%) (P < 0.05). The organ distribution of the infection and the level of colonization of infected organs did not differ significantly between infected animals in the various vaccine groups and those in the unvaccinated control group. No statistically significant relationship was detected between the magnitude of the antibody responses to the HS extract, to outer membrane proteins, or to the rough lipopolysaccharide, and freedom from infection. The results indicate that the HS extract of B. ovis may represent a useful alternative to B. melitensis Rev 1 or B. abortus 45/20 as a vaccine against B. ovis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236802     DOI: 10.1016/0165-2427(93)90198-d

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  10 in total

1.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

2.  Subcellular fractions of Brucella ovis distinctively induce the production of interleukin-2, interleukin-4, and interferon-gamma in mice.

Authors:  E Salas-Téllez; A Núñez del Arco; V Tenorio; E Díaz-Aparicio; M de la Garza; F Suárez-Güemes
Journal:  Can J Vet Res       Date:  2005-01       Impact factor: 1.310

3.  Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors:  M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

4.  Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry.

Authors:  R A Bowden; A Cloeckaert; M S Zygmunt; S Bernard; G Dubray
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

5.  The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice.

Authors:  Beatriz San Román; Victoria Garrido; Pilar-María Muñoz; Laura Arribillaga; Begoña García; Ximena De Andrés; Virginia Zabaleta; Cristina Mansilla; Inmaculada Farrán; Iñigo Lasa; Damián De Andrés; Beatriz Amorena; Juan-José Lasarte; María-Jesús Grilló
Journal:  Vet Res       Date:  2012-04-19       Impact factor: 3.683

6.  Mutants in the lipopolysaccharide of Brucella ovis are attenuated and protect against B. ovis infection in mice.

Authors:  Pedro Soler-Lloréns; Yolanda Gil-Ramírez; Ana Zabalza-Baranguá; Maite Iriarte; Raquel Conde-Álvarez; Amaia Zúñiga-Ripa; Beatriz San Román; Michel S Zygmunt; Nieves Vizcaíno; Axel Cloeckaert; María-Jesús Grilló; Ignacio Moriyón; Ignacio López-Goñi
Journal:  Vet Res       Date:  2014-07-17       Impact factor: 3.683

7.  A Brucella melitensis H38ΔwbkF rough mutant protects against Brucella ovis in rams.

Authors:  Pilar M Muñoz; Raquel Conde-Álvarez; Sara Andrés-Barranco; María-Jesús de Miguel; Amaia Zúñiga-Ripa; Beatriz Aragón-Aranda; Miriam Salvador-Bescós; Estrella Martínez-Gómez; Maite Iriarte; Montserrat Barberán; Nieves Vizcaíno; Ignacio Moriyón; José M Blasco
Journal:  Vet Res       Date:  2022-03-02       Impact factor: 3.683

8.  Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection.

Authors:  Pilar Sancho; Carmen Tejedor; Rebeca S Sidhu-Muñoz; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Vet Res       Date:  2014-06-04       Impact factor: 3.683

Review 9.  Development and trial of vaccines against Brucella.

Authors:  Jonathan Lalsiamthara; John Hwa Lee
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

10.  The CO2-dependence of Brucella ovis and Brucella abortus biovars is caused by defective carbonic anhydrases.

Authors:  Lara Pérez-Etayo; María Jesús de Miguel; Raquel Conde-Álvarez; Pilar M Muñoz; Mammar Khames; Maite Iriarte; Ignacio Moriyón; Amaia Zúñiga-Ripa
Journal:  Vet Res       Date:  2018-09-05       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.